Using high-throughput screening platforms, Creative Biolabs can quickly identify potential cardiotoxicity biomarkers. Meanwhile, in conjunction with modern bioinformatics analysis, we offer comprehensive and accurate biomarker identification services. Our advanced laboratory facilities and expert technical team enable us to perform functional validation of the identified biomarkers, including tests for their biological activity, specificity, and sensitivity.

Introduction

Cardiotoxicity is defined as the harm or impairment inflicted on the heart by specific drugs, chemotherapy treatments, or various therapeutic approaches. This can result in heart disease, heart failure, or other serious cardiovascular problems. Consequently, emphasizing the prevention and management of cardiotoxicity is essential.

Cardiotoxicity, is a heart damage caused by certain medications or treatments, potentially leading to serious issues such as arrhythmias and myocardial injury. Recent advancements in the study of biomarkers related to cardiotoxicity have offered new avenues for early screening, diagnosis, and treatment. As a result, Creative Biolabs has developed a range of biomarkers associated with cardiotoxicity, which includes markers for myocardial damage (such as troponin and B-type natriuretic peptide), inflammatory markers (like C-reactive protein), and those related to oxidative stress. These biomarkers can indicate structural and functional damage to the heart. Furthermore, we have designed specific miRNAs, which, when their expression levels are monitored, can provide early warnings for cardiotoxicity. In addition, we offer research services focused on characteristic proteins and metabolites related to cardiotoxicity. Our services not only help in understanding the mechanisms of cardiotoxicity but also lay the groundwork for the development of new biomarkers.

Fig.1 Anthracycline-related Cardiotoxicity Biomarker Screening.^1,3

Services

At Creative Biolabs, the process of developing biomarkers is intricate and usually requires a range of technical strategies and a variety of experimental techniques. Our biomarker development services encompass all stages from fundamental research to preclinical applications. This includes biomarker screening, where potential biomarkers are identified using techniques such as high-throughput sequencing, proteomics, and metabolomics. Following this, we conduct target validation through in vitro experiments and animal models to perform initial biological verification of the identified biomarkers. Finally, we carry out in-depth preclinical studies to assess the specificity and sensitivity of the biomarkers, laying the groundwork for subsequent clinical research.

• Genomic Levels

We utilize various methods, including DNA sequencing, gene expression analysis, and genome-wide association studies (GWAS), to identify genetic variations linked to diseases, thus revealing their genetic foundations. This data can enhance our understanding of individual genetic vulnerabilities, aiding in the development of early screening and preventive measures.

• Proteomic Levels

To assess protein levels and their alterations linked to diseases, we employ methods including mass spectrometry, ELISA, and WB techniques. These approaches enable us to provide functional biomarkers critical for assessing disease progression and prognosis.

• Metabolomic Levels

We utilize GC-MS and liquid chromatography-mass spectrometry (LC-MS) to analyze small molecule metabolites in biological specimens. By exploring how changes in these metabolites correlate with disease states, we aim to uncover both normal and abnormal physiological conditions within the organism.

• Cellomics Levels

By utilizing technologies such as flow cytometry and single-cell RNA sequencing, we continuously monitor changes at the cellular level associated with cardiotoxicity, aiding our clients in uncovering insights into the tumor microenvironment and immune responses.

• Bioinformatics Levels

Recently, Creative Biolabs has combined computational models with big data analysis techniques to integrate multi-omics data, conducting comprehensive analyses to identify biomarkers related to cardiotoxicity.

Fig.2 Potential Gene Biomarkers in Cardiotoxicity.^2,3

Advantages

• Cutting-edge research capabilities;
• Innovative technology platforms;
• Rigorous quality control;
• Strong client partnerships;
• Comprehensive technical support;
• Prompt delivery timelines.

Creative Biolabs possesses extensive experience and deep expertise in the development, production, and validation of cardiotoxicity biomarkers. Our laboratory is equipped with state-of-the-art analytical instruments that efficiently handle all phases of biomolecule development, characterization, and quantification. From the design and synthesis of the molecules to subsequent biological validation and preclinical application evaluation, we offer comprehensive solutions for our clients. If you require specialized services for cardiotoxicity biomarker development and validation, please feel free to contact us at any time.

References

1. Liu, Xiaomeng, Shuping Ge, and Aijun Zhang. "Pediatric Cardio-Oncology: Screening, Risk Stratification, and Prevention of Cardiotoxicity Associated with Anthracyclines." Children 11.7 (2024): 884.
2. Agarwal, Manusmriti, et al. "Interactions between genes altered during cardiotoxicity and neurotoxicity in zebrafish revealed using induced network modules analysis." Scientific Reports 13.1 (2023): 6257.
3. Distributed under Open Access license CC BY 4.0, without modification.

For Research Use Only | Not For Clinical Use